Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network

Hoster, Eva, Klapper, Wolfram, Hermine, Olivier, Kluin-Nelemans, Hanneke C., Walewski, Jan, van Hoof, Achiel, Trneny, Marek, Geisler, Christian H., Di Raimondo, Francesco, Szymczyk, Michal, Stilgenbauer, Stephan, Thieblemont, Catherine, Hallek, Michael, Forstpointner, Roswitha, Pott, Christiane, Ribrag, Vincent, Doorduijn, Jeanette, Hiddemann, Wolfgang, Dreyling, Martin H., Unterhalt, Michael · 2014 · Journal of Clinical Oncology

Abstract

Purpose: Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. External validation was planned to be performed on the cohort of the two recently completed randomized trials of the European MCL Network. Patients and Methods: Data of 958 patients with MCL (median age, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were pooled to assess the prognostic value of MIPI with respect to overall survival (OS) and time to treatment failure (TTF). Results: Five-year OS rates in MIPI low, intermediate, and high-risk groups were 83%, 63%, and 34%, respectively. The hazard ratios for OS of intermediate versus low and high versus intermediate risk patients were 2.1 (95% CI, 1.5 to 2.9) and 2.6 (2.0 to 3.3), respectively. MIPI was similarly prognostic for TTF. All four clinical baseline characteristics constituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic factors for OS and TTF. The validity of MIPI was independent of trial cohort and treatment strategy. Conclusion: MIPI was prospectively validated in a large MCL patient cohort homogenously treated according to recognized standards. As reflected in current guidelines, MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.52.2466

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 166

Metadata

Authors
Hoster, E., Klapper, W., Hermine, O., Kluin-Nelemans, H. C., Walewski, J., van Hoof, A., Trneny, M., Geisler, C. H., Di Raimondo, F., Szymczyk, M., Stilgenbauer, S., Thieblemont, C., Hallek, M., Forstpointner, R., Pott, C., Ribrag, V., Doorduijn, J., Hiddemann, W., Dreyling, M. H., & Unterhalt, M.
Venue
Journal of Clinical Oncology
Published
2014-05-01
Volume
32
Issue
13
Pages
1338-1346
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2049159227
Cited by
166
References
1
FWCI
13.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. https://app.cochat.ai/papers/10.1200/jco.2013.52.2466
The paper
Hoster, E., Klapper, W., Hermine, O., Kluin-Nelemans, H. C., Walewski, J., van Hoof, A., Trneny, M., Geisler, C. H., Di Raimondo, F., Szymczyk, M., Stilgenbauer, S., Thieblemont, C., Hallek, M., Forstpointner, R., Pott, C., Ribrag, V., Doorduijn, J., Hiddemann, W., Dreyling, M. H., & Unterhalt, M. (2014). Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.52.2466

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.